FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Millions	Jan. 31, 2022	Oct. 31, 2021	Jan. 31, 2021	Oct. 31, 2020
Assets
Short term investments	$ 45	$ 91
Liabilities
Contingent Consideration	92	89	$ 0	$ 0
Fair Value, Measurements, Recurring
Assets
Total assets measured at fair value	592	1,084
Total liabilities measured at fair value	134	128
Fair Value, Measurements, Recurring | Other Current Assets
Assets
Cash equivalents (money market funds)	465	919
Derivative instruments (foreign exchange contracts)	16	9
Short term investments	45	91
Fair Value, Measurements, Recurring | Other assets
Assets
Trading securities	37	34
Other investments	29	31
Fair Value, Measurements, Recurring | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	5	5
Contingent Consideration	65	62
Fair Value, Measurements, Recurring | Other long-term liabilities
Liabilities
Deferred compensation liability	37	34
Contingent Consideration	27	27
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets
Total assets measured at fair value	542	1,036
Total liabilities measured at fair value	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets
Assets
Cash equivalents (money market funds)	465	919
Derivative instruments (foreign exchange contracts)	0	0
Short term investments	40	83
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets
Assets
Trading securities	37	34
Other investments	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	0	0
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities
Liabilities
Deferred compensation liability	0	0
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Assets
Total assets measured at fair value	50	48
Total liabilities measured at fair value	42	39
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets
Assets
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	16	9
Short term investments	5	8
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets
Assets
Trading securities	0	0
Other investments	29	31
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	5	5
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities
Liabilities
Deferred compensation liability	37	34
Contingent Consideration	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Assets
Total assets measured at fair value	0	0
Total liabilities measured at fair value	92	89
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets
Assets
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Short term investments	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets
Assets
Trading securities	0	0
Other investments	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities
Liabilities
Derivative instruments (foreign exchange contracts)	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.
Liabilities
Contingent Consideration	65	62
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities
Liabilities
Deferred compensation liability	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc.
Liabilities
Contingent Consideration	$ 27	$ 27